8-K filed February 5, 2026, 6:59 PM ET ticker ATPC CIK 0001713210

regulatory confidence high sentiment negative materiality 0.85

Agape ATP receives Nasdaq delisting notice for low stock price; plans to appeal

Agape ATP Corp

Received delisting notice on Feb 2, 2026 under Low Priced Stocks rule (bid ≤ $0.10 for 10 days).
Also non-compliant with minimum bid price of $1.00 per share (Nasdaq Rule 5550(a)(2)).
Will request a hearing by Feb 9, 2026 to stay suspension; hearing fee is $20,000.
Stock trades on Nasdaq Capital Market under symbol ATPC.

item 3.01 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-005211
form_type: 8-K
ticker: ATPC
cik: 0001713210
company_name: Agape ATP Corp
filed_at: 2026-02-05T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.980177+00:00
generated_at: 2026-05-16T04:29:16.335318+00:00
sec_items: ["3.01", "7.01", "9.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-005211
json_url: https://secwatch.observer/filing/0001493152-26-005211.json
markdown_url: https://secwatch.observer/filing/0001493152-26-005211.md
text_url: https://secwatch.observer/filing/0001493152-26-005211.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1713210/000149315226005211/0001493152-26-005211-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1713210/000149315226005211/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

1b0c8c9fdda3f34cf329e66025d7a71e33b832f6

Agape ATP Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

a00f2f79abb38549ec54e6226d25dd4c53a8374c

Agape ATP Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).

February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to delist the Company’s securities. The Staff’s determination was based on that as of January 30, 2026, the Company’s securities had a closing bid of $0.10 or less for the last ten consecutive trading days, and accordingly, is subject to the provisions under Listing Rule 5810(c)(3)(A)(iii), the “Low Priced Stocks” Rule. The Company has the opportunity to request a hearing with the Hearings Panel (the “Panel”), by February 9, 2026. The Company intends to make the request

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

ATNM

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc. May 29, 2026, 5:10 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

Comparable filing

May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately

Filing page SEC filing

VSTD

Vestand receives Nasdaq delisting notice for late quarterly and annual filings

Vestand Inc. May 26, 2026, 5:18 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

Comparable filing

May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying it that Nasdaq has initiated a process which could result in the delisting of the Company’s secu

Filing page SEC filing

NVVE

Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review

Nuvve Holding Corp. May 22, 2026, 6:35 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

Comparable filing

May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company

Filing page SEC filing

AGAE

AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal

Allied Gaming & Entertainment Inc. May 11, 2026, 5:09 PM ET regulatory Items 3.01, 5.03, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

Comparable filing

termination before an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company that the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did not comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant to Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during a 180-day compliance period and is not eligible for a second 180-day complian

Filing page SEC filing

SBEV

Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M

SPLASH BEVERAGE GROUP, INC. May 5, 2026, 7:59 PM ET regulatory Items 1.01, 1.02, 3.01, 3.02, 5.03, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

Comparable filing

April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”) that the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined in Section 1

Filing page SEC filing

VSTD

Vestand receives Nasdaq delisting notice for late 10-K filing; may submit compliance plan by May 18, 2026

Vestand Inc. April 29, 2026, 7:59 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

Comparable filing

April 23, 2026, Vestand Inc. (the “Company”) received a staff deficiency notice (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-K for the

Filing page SEC filing

JAGX

Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split

Jaguar Health, Inc. April 27, 2026, 7:59 PM ET regulatory Items 3.01, 3.03, 5.03, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

Comparable filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Filing page SEC filing

ONFO

Onfolio receives Nasdaq delisting notice for insufficient equity ($1.22M vs $2.5M min)

Onfolio Holdings, Inc May 29, 2026, 4:30 PM ET regulatory Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: regulatory similar materiality

This filing

January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to del

Comparable filing

May 26, 2026, Onfolio Holdings Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Quarterly Report on Form 10-Q for the for the period ended March 31, 2026 reported stockholders’ equity of $1,216,603. As of the date of the Notice

Filing page SEC filing

Source: SEC EDGAR

accession 0001493152-26-005211

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.